JP2026015500A5 - - Google Patents
Info
- Publication number
- JP2026015500A5 JP2026015500A5 JP2025194419A JP2025194419A JP2026015500A5 JP 2026015500 A5 JP2026015500 A5 JP 2026015500A5 JP 2025194419 A JP2025194419 A JP 2025194419A JP 2025194419 A JP2025194419 A JP 2025194419A JP 2026015500 A5 JP2026015500 A5 JP 2026015500A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- antigen
- antibody
- binding fragment
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2020/105286 | 2020-07-28 | ||
| CN2020105286 | 2020-07-28 | ||
| CN2021098476 | 2021-06-04 | ||
| CNPCT/CN2021/098476 | 2021-06-04 | ||
| JP2023505901A JP2023540436A (ja) | 2020-07-28 | 2021-07-27 | Ｐｄ－ｌ１およびｔｇｆ－βを標的とする二機能性分子 |
| PCT/CN2021/108643 WO2022022503A1 (en) | 2020-07-28 | 2021-07-27 | Bifunctional molecules targeting pd-l1 and tgf-beta |
| JP2024187749A JP7846734B2 (ja) | 2020-07-28 | 2024-10-24 | Ｐｄ－ｌ１およびｔｇｆ－βを標的とする二機能性分子 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024187749A Division JP7846734B2 (ja) | 2020-07-28 | 2024-10-24 | Ｐｄ－ｌ１およびｔｇｆ－βを標的とする二機能性分子 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2026015500A JP2026015500A (ja) | 2026-01-29 |
| JP2026015500A5 true JP2026015500A5 (cg-RX-API-DMAC10.html) | 2026-03-25 |
Family
ID=80037607
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023505901A Withdrawn JP2023540436A (ja) | 2020-07-28 | 2021-07-27 | Ｐｄ－ｌ１およびｔｇｆ－βを標的とする二機能性分子 |
| JP2024187749A Active JP7846734B2 (ja) | 2020-07-28 | 2024-10-24 | Ｐｄ－ｌ１およびｔｇｆ－βを標的とする二機能性分子 |
| JP2025194419A Pending JP2026015500A (ja) | 2020-07-28 | 2025-11-13 | Ｐｄ－ｌ１およびｔｇｆ－βを標的とする二機能性分子 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023505901A Withdrawn JP2023540436A (ja) | 2020-07-28 | 2021-07-27 | Ｐｄ－ｌ１およびｔｇｆ－βを標的とする二機能性分子 |
| JP2024187749A Active JP7846734B2 (ja) | 2020-07-28 | 2024-10-24 | Ｐｄ－ｌ１およびｔｇｆ－βを標的とする二機能性分子 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230287125A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4188950A4 (cg-RX-API-DMAC10.html) |
| JP (3) | JP2023540436A (cg-RX-API-DMAC10.html) |
| KR (1) | KR20230050356A (cg-RX-API-DMAC10.html) |
| CN (4) | CN121319180A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2021317376A1 (cg-RX-API-DMAC10.html) |
| IL (1) | IL299966A (cg-RX-API-DMAC10.html) |
| PH (1) | PH12023550193A1 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2022022503A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL322840A (en) * | 2023-02-20 | 2025-10-01 | Akeso Biopharma Co Ltd | Fusion protein comprising a TGF-βRII extracellular region fragment, its pharmaceutical composition and use |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20210977T1 (hr) * | 2014-02-10 | 2021-09-17 | Merck Patent Gmbh | Ciljano inhibiranje tgf beta |
| WO2017020291A1 (en) * | 2015-08-06 | 2017-02-09 | Wuxi Biologics (Shanghai) Co. Ltd. | Novel anti-pd-l1 antibodies |
| JP7080213B2 (ja) * | 2016-03-23 | 2022-06-03 | スーチョウ トランセンタ セラピューティクス カンパニー，リミテッド | 新規抗ｐｄ－ｌ１抗体 |
| CN107686520B (zh) * | 2016-08-04 | 2023-01-03 | 信达生物制药(苏州)有限公司 | 抗pd-l1纳米抗体及其应用 |
| CN110023338A (zh) * | 2016-12-08 | 2019-07-16 | 伊莱利利公司 | 用于与抗pd-l1抗体组合的抗tim-3抗体 |
| CN110050000B (zh) * | 2017-05-12 | 2022-07-26 | 苏州盛迪亚生物医药有限公司 | 含有TGF-β受体的融合蛋白及其医药用途 |
| CN109575140B (zh) * | 2017-09-29 | 2021-02-23 | 北京比洋生物技术有限公司 | 靶向pd-1或pd-l1且靶向vegf家族的双靶向融合蛋白及其用途 |
| EP3470429A1 (en) * | 2017-10-10 | 2019-04-17 | Numab Innovation AG | Antibodies targeting pdl1 and methods of use thereof |
| CN109721657B (zh) * | 2017-10-27 | 2021-11-02 | 北京比洋生物技术有限公司 | 阻断pd-1/pd-l1信号传导途径且活化t细胞的融合蛋白及其用途 |
| JP7348899B2 (ja) * | 2017-12-08 | 2023-09-21 | マレンゴ・セラピューティクス，インコーポレーテッド | 多重特異性分子及びその使用 |
| BR112020019827A2 (pt) * | 2018-03-29 | 2021-01-05 | I-Mab Biopharma Us Limited | Anticorpo ou fragmento do mesmo, anticorpo biespecífico, composição, polinucleotídeo nucleotídeo, célula isolada, e, métodos para tratar câncer ou infecção e detectar a expressão de pd-l1 em uma amostra |
| CN113271962A (zh) * | 2018-08-22 | 2021-08-17 | 默克专利有限公司 | 利用靶向TGF-β抑制的三阴性乳腺癌的治疗 |
| CA3118415A1 (en) * | 2018-11-09 | 2020-05-14 | Jiangsu Hengrui Medicine Co., Ltd. | Tgf-.beta. receptor fusion protein pharmaceutical composition and use thereof |
| EP3990116A1 (en) * | 2019-06-28 | 2022-05-04 | Gensun Biopharma Inc. | ANTITUMOR ANTAGONIST CONSISTING OF A MUTATED TGFß1 - RII EXTRACELLULAR DOMAIN AND AN IMMUNOGLOBULIN SCAFFOLD |
| US11028174B1 (en) * | 2020-07-28 | 2021-06-08 | Lepu Biopharma Co., Ltd. | Bifunctional molecules targeting PD-L1 and TGF-β |
| CN112940134B (zh) * | 2021-05-11 | 2021-09-03 | 正大天晴药业集团南京顺欣制药有限公司 | 针对PD-1和TGF-β的双功能蛋白 |
-
2021
- 2021-07-27 CN CN202511294608.4A patent/CN121319180A/zh active Pending
- 2021-07-27 CN CN202411428806.0A patent/CN119409832B/zh active Active
- 2021-07-27 JP JP2023505901A patent/JP2023540436A/ja not_active Withdrawn
- 2021-07-27 AU AU2021317376A patent/AU2021317376A1/en not_active Abandoned
- 2021-07-27 CN CN202411428879.XA patent/CN119462927B/zh active Active
- 2021-07-27 KR KR1020237006251A patent/KR20230050356A/ko not_active Ceased
- 2021-07-27 EP EP21849817.8A patent/EP4188950A4/en active Pending
- 2021-07-27 WO PCT/CN2021/108643 patent/WO2022022503A1/en not_active Ceased
- 2021-07-27 CN CN202180061312.1A patent/CN116348493B/zh active Active
- 2021-07-27 PH PH1/2023/550193A patent/PH12023550193A1/en unknown
- 2021-07-27 IL IL299966A patent/IL299966A/en unknown
- 2021-07-27 US US18/007,265 patent/US20230287125A1/en active Pending
-
2024
- 2024-10-24 JP JP2024187749A patent/JP7846734B2/ja active Active
-
2025
- 2025-11-13 JP JP2025194419A patent/JP2026015500A/ja active Pending